BioLineRx, Ltd. – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “BioLineRx, Ltd. - Product Pipeline Review - 2012” provides data on the BioLineRx, Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, BioLineRx, Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from BioLineRx, Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Current R&D Portfolio of BioLineRx, Ltd.; BioLineRx, Ltd. - Key Therapeutics; BioLineRx, Ltd. - Pipeline Overview and Promising Molecules; BioLineRx, Ltd. - News; BioLineRx, Ltd. - Latest Updates; BioLineRx, Ltd. - Pipeline; BioLineRx, Ltd. - Discontinued/Dormant Projects
Summary
Global Market Direct’s pharmaceuticals report, “BioLineRx, Ltd. - Product Pipeline Review - 2012” provides data on the BioLineRx, Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, BioLineRx, Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from BioLineRx, Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- BioLineRx, Ltd. - Brief BioLineRx, Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of BioLineRx, Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of BioLineRx, Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the BioLineRx, Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate BioLineRx, Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of BioLineRx, Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the BioLineRx, Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with BioLineRx, Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of BioLineRx, Ltd. and identify potential opportunities in those areas.
Current R&D Portfolio of BioLineRx, Ltd.; BioLineRx, Ltd. - Key Therapeutics; BioLineRx, Ltd. - Pipeline Overview and Promising Molecules; BioLineRx, Ltd. - News; BioLineRx, Ltd. - Latest Updates; BioLineRx, Ltd. - Pipeline; BioLineRx, Ltd. - Discontinued/Dormant Projects
BioLineRx, Ltd. Snapshot
BioLineRx, Ltd. Overview
Key Information
Key Facts
BioLineRx, Ltd. – Research and Development Overview
Key Therapeutic Areas
BioLineRx, Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
BioLineRx, Ltd. – Pipeline Products Glance
BioLineRx, Ltd. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
BioLineRx, Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
BioLineRx, Ltd. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
BioLineRx, Ltd. – Drug Profiles
BL-1020
Product Description
Mechanism of Action
R&D Progress
BL-1021
Product Description
Mechanism of Action
R&D Progress
BL-1023
Product Description
Mechanism of Action
R&D Progress
BL-4010
Product Description
Mechanism of Action
R&D Progress
BL-5030
Product Description
Mechanism of Action
R&D Progress
BL-5040
Product Description
Mechanism of Action
R&D Progress
BL-6010
Product Description
Mechanism of Action
R&D Progress
BL-6020
Product Description
Mechanism of Action
R&D Progress
BL-6031
Product Description
Mechanism of Action
R&D Progress
BL-6040
Product Description
Mechanism of Action
R&D Progress
BL-7010
Product Description
Mechanism of Action
R&D Progress
BL-7020
Product Description
Mechanism of Action
R&D Progress
BL-7030
Product Description
Mechanism of Action
R&D Progress
BL-7040
Product Description
Mechanism of Action
R&D Progress
BL-7050
Product Description
Mechanism of Action
R&D Progress
BL-8020
Product Description
Mechanism of Action
R&D Progress
BL-8030
Product Description
Mechanism of Action
R&D Progress
BioLineRx, Ltd. – Pipeline Analysis
BioLineRx, Ltd. – Pipeline Products by Therapeutic Class
BioLineRx, Ltd. – Pipeline Products By Target
BioLineRx, Ltd. – Pipeline Products by Route of Administration
BioLineRx, Ltd. – Pipeline Products By Mechanism of Action
BioLineRx, Ltd. – Recent Pipeline Updates
BioLineRx, Ltd. - Dormant Projects
BioLineRx, Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
BL-1050
BL-2030
BL-4040
BL-4060
BL-5020
BioLineRx, Ltd. – Company Statement
BioLineRx, Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
BioLineRx, Ltd., Recent Developments
BioLineRx, Ltd.- Press Release
Apr 30, 2012: Tel Aviv University Researchers Develop New Drug To Treat Neuropathic Pain
Mar 07, 2012: BioLineRx Receives European Patent For BL-1020
Mar 05, 2012: BioLineRx Receives Approval For Initiating Phase II Clinical Trial Of BL-7040
Feb 21, 2012: BioLineRx Announces Publication Of Pre-Clinical Results Demonstrating Efficacy Of BL-7010 In Reducing Gluten Toxicity
Dec 07, 2009: Santhera Presents New Data On MC-4R Antagonist Program For Treatment Of Cancer Cachexia
Sep 24, 2009: BioLineRx Announces That EAGLE Trial With BL-1020 Signals Breakthrough In The Treatment of Schizophrenia
Sep 14, 2009: BioLineRx Announces Positive Topline Results Of BL-1020 For The Treatment Of Schizophrenia
Jun 21, 2009: BioLineRx Announces New Results Confirming The Mode Of Action Of Its Anti-Psychotic Drug- BL-1020
Jun 21, 2009: BioLineRx Initiates Phase I/II Trial Of BL-5010, A Novel Formulation For The Non Surgical Removal Of Skin Lesions
May 18, 2009: BioLineRx Presents Data At SOBP Demonstrating Potential Benefit Of BL-1020 In Improving Cognition
Apr 30, 2009: BioLineRx Completes Recruitment For Its BL-1020 Phase IIb EAGLE Study In Schizophrenia
Mar 20, 2009: Publication Highlights Potential Of Santhera's Oral MC4-Receptor Antagonist Program For Treatment Of Cancer Cachexia
Financial Deals Landscape
BioLineRx, Ltd., Deals Summary
BioLineRx, Ltd., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
BioLineRx Secures Additional $9 Million In Financing
BioLineRx Secures $15 Million In Venture Financing
Partnerships
BioLineRx Enters Into Co-Development Agreement With Compugen
Capstone Therapeutics Enters Into Co-Development Agreement With BioLineRx
Licensing Agreements
Cypress Bioscience Enters Into Licensing Agreement With BioLineRx
BioLineRx Enters Into Licensing Agreement With University Of Illinois
BioLineRx Enters Into Licensing Agreement With Gevys Pharma
BioLineRx Enters Into Licensing Agreement With Genoscience Pharma And RFS Pharma For BL-8030
BioLineRx Enters Into Licensing Agreement With Genoscience For BL-8020
BioLineRx Enters Into Licensing Agreement With Ramot At Tel Aviv University For BL-7050
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-7040
BioLineRx Enters Into Licensing Agreement With Algen BioPharma For BL-7030
Santhera Pharma Enters Into Licensing Agreement With BioLineRx
BioLineRx Enters Into Licensing Agreement With Ikaria Holdings
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-5040
BioLineRx Enters Into Licensing Agreement With Innovative Pharma
BioLineRx Enters Into Licensing Agreement With Yissum Research Development And Hadasit
BioLineRx Enters Into Licensing Agreement With Yeda Research For BL-4050
BioLineRx Enters Into Licensing Agreement With Gene Vector
BioLineRx Enters Into Licensing Agreement With Yeda Research For BL-3050
BioLineRx Enters Into Licensing Agreement With Yeda Research And The Tel Aviv Sourasky Medical Center
BioLineRx Enters Into Licensing Agreement With Yissum Research Development And Ramot
BioLineRx Enters Into Licensing Agreement With PolyGene And Efrat BioPolymers
BioLineRx Enters Into Licensing Agreement With B.G. Negev And Mor Research
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-3020
BioLineRx Enters Into Licensing Agreement With Ramot at Tel Aviv University
BioLineRx Enters Into Licensing Agreement With The Technion Research and Development Foundations
BioLineRx Enters Into Licensing Agreement With BioRap Technologies
BioLineRx Enters Into Licensing Agreement With Yeda Research For BL-2040
BioLineRx Enters Into Licensing Agreement With Galmed International
Rimonyx Enters Into Licensing Agreement With BioLineRx
BioLineRx Enters Into Licensing Agreement With BGN Technologies
BioLineRx Enters Into Licensing Agreement With Rimonyx Pharma
BioLineRx Enters Into Licensing Agreement With Ramot at Tel Aviv University And Bar Ilan University
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-1050
BioLineRx Enters Into Licensing Agreement With Ramot at Tel Aviv University And Bar Ilan Research
Equity Offering
BioLineRx Completes Private Placement Of American Depositary Shares For $15 Million
BioLineRx Completes Public Offering Of $12.3 Million
BioLineRx Completes Rights Issue Of Common Stock For $13.7 Million
BioLineRx Completes IPO Of $50 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
BioLineRx, Ltd., Key Information
BioLineRx, Ltd., Key Facts
BioLineRx, Ltd. – Pipeline by Indication, 2012
BioLineRx, Ltd. – Pipeline by Stage of Development, 2012
BioLineRx, Ltd. – Monotherapy Products in Pipeline, 2012
BioLineRx, Ltd. – Phase III, 2012
BioLineRx, Ltd. – Phase II, 2012
BioLineRx, Ltd. – Phase I, 2012
BioLineRx, Ltd. – Pre-Clinical, 2012
BioLineRx, Ltd. – Pipeline By Therapeutic Class, 2012
BioLineRx, Ltd. - Pipeline By Target, 2012
BioLineRx, Ltd. – Pipeline By Route of Administration, 2012
BioLineRx, Ltd. – Pipeline Products By Mechanism of Action, 2012
BioLineRx, Ltd. – Recent Pipeline Updates, 2012
BioLineRx, Ltd. - Dormant Developmental Projects,2012
BioLineRx, Ltd. - Discontinued Pipeline Products, 2012
BioLineRx, Ltd., Subsidiaries
BioLineRx, Ltd., Deals Summary
BioLineRx Secures Additional $9 Million In Financing
BioLineRx Secures $15 Million In Venture Financing
BioLineRx Enters Into Co-Development Agreement With Compugen
Capstone Therapeutics Enters Into Co-Development Agreement With BioLineRx
Cypress Bioscience Enters Into Licensing Agreement With BioLineRx
BioLineRx Enters Into Licensing Agreement With University Of Illinois
BioLineRx Enters Into Licensing Agreement With Gevys Pharma
BioLineRx Enters Into Licensing Agreement With Genoscience Pharma And RFS Pharma For BL-8030
BioLineRx Enters Into Licensing Agreement With Genoscience For BL-8020
BioLineRx Enters Into Licensing Agreement With Ramot At Tel Aviv University For BL-7050
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-7040
BioLineRx Enters Into Licensing Agreement With Algen BioPharma For BL-7030
Santhera Pharma Enters Into Licensing Agreement With BioLineRx
BioLineRx Enters Into Licensing Agreement With Ikaria Holdings
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-5040
BioLineRx Enters Into Licensing Agreement With Innovative Pharma
BioLineRx Enters Into Licensing Agreement With Yissum Research Development And Hadasit
BioLineRx Enters Into Licensing Agreement With Yeda Research For BL-4050
BioLineRx Enters Into Licensing Agreement With Gene Vector
BioLineRx Enters Into Licensing Agreement With Yeda Research For BL-3050
BioLineRx Enters Into Licensing Agreement With Yeda Research And The Tel Aviv Sourasky Medical Center
BioLineRx Enters Into Licensing Agreement With Yissum Research Development And Ramot
BioLineRx Enters Into Licensing Agreement With PolyGene And Efrat BioPolymers
BioLineRx Enters Into Licensing Agreement With B.G. Negev And Mor Research
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-3020
BioLineRx Enters Into Licensing Agreement With Ramot at Tel Aviv University
BioLineRx Enters Into Licensing Agreement With The Technion Research and Development Foundations
BioLineRx Enters Into Licensing Agreement With BioRap Technologies
BioLineRx Enters Into Licensing Agreement With Yeda Research For BL-2040
BioLineRx Enters Into Licensing Agreement With Galmed International
Rimonyx Enters Into Licensing Agreement With BioLineRx
BioLineRx Enters Into Licensing Agreement With BGN Technologies
BioLineRx Enters Into Licensing Agreement With Rimonyx Pharma
BioLineRx Enters Into Licensing Agreement With Ramot at Tel Aviv University And Bar Ilan University
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-1050
BioLineRx Enters Into Licensing Agreement With Ramot at Tel Aviv University And Bar Ilan Research
BioLineRx Completes Private Placement Of American Depositary Shares For $15 Million
BioLineRx Completes Public Offering Of $12.3 Million
BioLineRx Completes Rights Issue Of Common Stock For $13.7 Million
BioLineRx Completes IPO Of $50 Million
LIST OF FIGURES
BioLineRx, Ltd. – Pipeline by Indication, 2012
BioLineRx, Ltd. – Pipeline by Stage of Development, 2012
BioLineRx, Ltd. – Monotherapy Products in Pipeline, 2012
BioLineRx, Ltd. – Pipeline By Therapeutic Class, 2012
BioLineRx, Ltd. - Pipeline By Target, 2012
BioLineRx, Ltd. – Pipeline By Route of Administration, 2012
BioLineRx, Ltd. - Pipeline Products By Mechanism of Action, 2012
BioLineRx, Ltd. Overview
Key Information
Key Facts
BioLineRx, Ltd. – Research and Development Overview
Key Therapeutic Areas
BioLineRx, Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
BioLineRx, Ltd. – Pipeline Products Glance
BioLineRx, Ltd. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
BioLineRx, Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
BioLineRx, Ltd. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
BioLineRx, Ltd. – Drug Profiles
BL-1020
Product Description
Mechanism of Action
R&D Progress
BL-1021
Product Description
Mechanism of Action
R&D Progress
BL-1023
Product Description
Mechanism of Action
R&D Progress
BL-4010
Product Description
Mechanism of Action
R&D Progress
BL-5030
Product Description
Mechanism of Action
R&D Progress
BL-5040
Product Description
Mechanism of Action
R&D Progress
BL-6010
Product Description
Mechanism of Action
R&D Progress
BL-6020
Product Description
Mechanism of Action
R&D Progress
BL-6031
Product Description
Mechanism of Action
R&D Progress
BL-6040
Product Description
Mechanism of Action
R&D Progress
BL-7010
Product Description
Mechanism of Action
R&D Progress
BL-7020
Product Description
Mechanism of Action
R&D Progress
BL-7030
Product Description
Mechanism of Action
R&D Progress
BL-7040
Product Description
Mechanism of Action
R&D Progress
BL-7050
Product Description
Mechanism of Action
R&D Progress
BL-8020
Product Description
Mechanism of Action
R&D Progress
BL-8030
Product Description
Mechanism of Action
R&D Progress
BioLineRx, Ltd. – Pipeline Analysis
BioLineRx, Ltd. – Pipeline Products by Therapeutic Class
BioLineRx, Ltd. – Pipeline Products By Target
BioLineRx, Ltd. – Pipeline Products by Route of Administration
BioLineRx, Ltd. – Pipeline Products By Mechanism of Action
BioLineRx, Ltd. – Recent Pipeline Updates
BioLineRx, Ltd. - Dormant Projects
BioLineRx, Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
BL-1050
BL-2030
BL-4040
BL-4060
BL-5020
BioLineRx, Ltd. – Company Statement
BioLineRx, Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
BioLineRx, Ltd., Recent Developments
BioLineRx, Ltd.- Press Release
Apr 30, 2012: Tel Aviv University Researchers Develop New Drug To Treat Neuropathic Pain
Mar 07, 2012: BioLineRx Receives European Patent For BL-1020
Mar 05, 2012: BioLineRx Receives Approval For Initiating Phase II Clinical Trial Of BL-7040
Feb 21, 2012: BioLineRx Announces Publication Of Pre-Clinical Results Demonstrating Efficacy Of BL-7010 In Reducing Gluten Toxicity
Dec 07, 2009: Santhera Presents New Data On MC-4R Antagonist Program For Treatment Of Cancer Cachexia
Sep 24, 2009: BioLineRx Announces That EAGLE Trial With BL-1020 Signals Breakthrough In The Treatment of Schizophrenia
Sep 14, 2009: BioLineRx Announces Positive Topline Results Of BL-1020 For The Treatment Of Schizophrenia
Jun 21, 2009: BioLineRx Announces New Results Confirming The Mode Of Action Of Its Anti-Psychotic Drug- BL-1020
Jun 21, 2009: BioLineRx Initiates Phase I/II Trial Of BL-5010, A Novel Formulation For The Non Surgical Removal Of Skin Lesions
May 18, 2009: BioLineRx Presents Data At SOBP Demonstrating Potential Benefit Of BL-1020 In Improving Cognition
Apr 30, 2009: BioLineRx Completes Recruitment For Its BL-1020 Phase IIb EAGLE Study In Schizophrenia
Mar 20, 2009: Publication Highlights Potential Of Santhera's Oral MC4-Receptor Antagonist Program For Treatment Of Cancer Cachexia
Financial Deals Landscape
BioLineRx, Ltd., Deals Summary
BioLineRx, Ltd., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
BioLineRx Secures Additional $9 Million In Financing
BioLineRx Secures $15 Million In Venture Financing
Partnerships
BioLineRx Enters Into Co-Development Agreement With Compugen
Capstone Therapeutics Enters Into Co-Development Agreement With BioLineRx
Licensing Agreements
Cypress Bioscience Enters Into Licensing Agreement With BioLineRx
BioLineRx Enters Into Licensing Agreement With University Of Illinois
BioLineRx Enters Into Licensing Agreement With Gevys Pharma
BioLineRx Enters Into Licensing Agreement With Genoscience Pharma And RFS Pharma For BL-8030
BioLineRx Enters Into Licensing Agreement With Genoscience For BL-8020
BioLineRx Enters Into Licensing Agreement With Ramot At Tel Aviv University For BL-7050
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-7040
BioLineRx Enters Into Licensing Agreement With Algen BioPharma For BL-7030
Santhera Pharma Enters Into Licensing Agreement With BioLineRx
BioLineRx Enters Into Licensing Agreement With Ikaria Holdings
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-5040
BioLineRx Enters Into Licensing Agreement With Innovative Pharma
BioLineRx Enters Into Licensing Agreement With Yissum Research Development And Hadasit
BioLineRx Enters Into Licensing Agreement With Yeda Research For BL-4050
BioLineRx Enters Into Licensing Agreement With Gene Vector
BioLineRx Enters Into Licensing Agreement With Yeda Research For BL-3050
BioLineRx Enters Into Licensing Agreement With Yeda Research And The Tel Aviv Sourasky Medical Center
BioLineRx Enters Into Licensing Agreement With Yissum Research Development And Ramot
BioLineRx Enters Into Licensing Agreement With PolyGene And Efrat BioPolymers
BioLineRx Enters Into Licensing Agreement With B.G. Negev And Mor Research
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-3020
BioLineRx Enters Into Licensing Agreement With Ramot at Tel Aviv University
BioLineRx Enters Into Licensing Agreement With The Technion Research and Development Foundations
BioLineRx Enters Into Licensing Agreement With BioRap Technologies
BioLineRx Enters Into Licensing Agreement With Yeda Research For BL-2040
BioLineRx Enters Into Licensing Agreement With Galmed International
Rimonyx Enters Into Licensing Agreement With BioLineRx
BioLineRx Enters Into Licensing Agreement With BGN Technologies
BioLineRx Enters Into Licensing Agreement With Rimonyx Pharma
BioLineRx Enters Into Licensing Agreement With Ramot at Tel Aviv University And Bar Ilan University
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-1050
BioLineRx Enters Into Licensing Agreement With Ramot at Tel Aviv University And Bar Ilan Research
Equity Offering
BioLineRx Completes Private Placement Of American Depositary Shares For $15 Million
BioLineRx Completes Public Offering Of $12.3 Million
BioLineRx Completes Rights Issue Of Common Stock For $13.7 Million
BioLineRx Completes IPO Of $50 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
BioLineRx, Ltd., Key Information
BioLineRx, Ltd., Key Facts
BioLineRx, Ltd. – Pipeline by Indication, 2012
BioLineRx, Ltd. – Pipeline by Stage of Development, 2012
BioLineRx, Ltd. – Monotherapy Products in Pipeline, 2012
BioLineRx, Ltd. – Phase III, 2012
BioLineRx, Ltd. – Phase II, 2012
BioLineRx, Ltd. – Phase I, 2012
BioLineRx, Ltd. – Pre-Clinical, 2012
BioLineRx, Ltd. – Pipeline By Therapeutic Class, 2012
BioLineRx, Ltd. - Pipeline By Target, 2012
BioLineRx, Ltd. – Pipeline By Route of Administration, 2012
BioLineRx, Ltd. – Pipeline Products By Mechanism of Action, 2012
BioLineRx, Ltd. – Recent Pipeline Updates, 2012
BioLineRx, Ltd. - Dormant Developmental Projects,2012
BioLineRx, Ltd. - Discontinued Pipeline Products, 2012
BioLineRx, Ltd., Subsidiaries
BioLineRx, Ltd., Deals Summary
BioLineRx Secures Additional $9 Million In Financing
BioLineRx Secures $15 Million In Venture Financing
BioLineRx Enters Into Co-Development Agreement With Compugen
Capstone Therapeutics Enters Into Co-Development Agreement With BioLineRx
Cypress Bioscience Enters Into Licensing Agreement With BioLineRx
BioLineRx Enters Into Licensing Agreement With University Of Illinois
BioLineRx Enters Into Licensing Agreement With Gevys Pharma
BioLineRx Enters Into Licensing Agreement With Genoscience Pharma And RFS Pharma For BL-8030
BioLineRx Enters Into Licensing Agreement With Genoscience For BL-8020
BioLineRx Enters Into Licensing Agreement With Ramot At Tel Aviv University For BL-7050
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-7040
BioLineRx Enters Into Licensing Agreement With Algen BioPharma For BL-7030
Santhera Pharma Enters Into Licensing Agreement With BioLineRx
BioLineRx Enters Into Licensing Agreement With Ikaria Holdings
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-5040
BioLineRx Enters Into Licensing Agreement With Innovative Pharma
BioLineRx Enters Into Licensing Agreement With Yissum Research Development And Hadasit
BioLineRx Enters Into Licensing Agreement With Yeda Research For BL-4050
BioLineRx Enters Into Licensing Agreement With Gene Vector
BioLineRx Enters Into Licensing Agreement With Yeda Research For BL-3050
BioLineRx Enters Into Licensing Agreement With Yeda Research And The Tel Aviv Sourasky Medical Center
BioLineRx Enters Into Licensing Agreement With Yissum Research Development And Ramot
BioLineRx Enters Into Licensing Agreement With PolyGene And Efrat BioPolymers
BioLineRx Enters Into Licensing Agreement With B.G. Negev And Mor Research
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-3020
BioLineRx Enters Into Licensing Agreement With Ramot at Tel Aviv University
BioLineRx Enters Into Licensing Agreement With The Technion Research and Development Foundations
BioLineRx Enters Into Licensing Agreement With BioRap Technologies
BioLineRx Enters Into Licensing Agreement With Yeda Research For BL-2040
BioLineRx Enters Into Licensing Agreement With Galmed International
Rimonyx Enters Into Licensing Agreement With BioLineRx
BioLineRx Enters Into Licensing Agreement With BGN Technologies
BioLineRx Enters Into Licensing Agreement With Rimonyx Pharma
BioLineRx Enters Into Licensing Agreement With Ramot at Tel Aviv University And Bar Ilan University
BioLineRx Enters Into Licensing Agreement With Yissum Research Development For BL-1050
BioLineRx Enters Into Licensing Agreement With Ramot at Tel Aviv University And Bar Ilan Research
BioLineRx Completes Private Placement Of American Depositary Shares For $15 Million
BioLineRx Completes Public Offering Of $12.3 Million
BioLineRx Completes Rights Issue Of Common Stock For $13.7 Million
BioLineRx Completes IPO Of $50 Million
LIST OF FIGURES
BioLineRx, Ltd. – Pipeline by Indication, 2012
BioLineRx, Ltd. – Pipeline by Stage of Development, 2012
BioLineRx, Ltd. – Monotherapy Products in Pipeline, 2012
BioLineRx, Ltd. – Pipeline By Therapeutic Class, 2012
BioLineRx, Ltd. - Pipeline By Target, 2012
BioLineRx, Ltd. – Pipeline By Route of Administration, 2012
BioLineRx, Ltd. - Pipeline Products By Mechanism of Action, 2012
